scrambled CCM. Control media (CM) was produced in the same way without MSCs secretions. Rats were anesthetized and underwent pudendal nerve crush (PNC) followed by vaginal distension (VD). Rats received a 300 ml intraperitoneal injection of either CM, BDNF KD CCM, scrambled CCM, control CCM or CM, one hour and 1 week after surgery. Three weeks after injury, leak point pressure (LPP) and pudendal nerve sensory branch potential (PNSBP) were recorded and analysed to assess urethral function and pudendal nerve recovery (P<0.05). The urethra and pudendal nerve were harvested for anatomical assessment.
INTRODUCTION AND OBJECTIVES: Skeletal muscle progenitor cells (MPCs) are considered a key candidate for cell therapy in the treatment of skeletal muscle injuries, such as stress urinary incontinence due to urethral sphincter dysfunction. However, it is challenging to expand sufficient functional skeletal muscle cells in vitro from a small tissue biopsy because skeletal myocytes often decrease their phenotypic expression in culture conditions. Thus, we sought to develop a better culture system for expansion and differentiation of human MPCs to be used for bioprinting for myogenesis or cell therapy in vivo to treat urinary incontinence.
METHODS: Porcine-derived muscle extracellular matrix (ECM) was generated via decellularization methods with distilled water, 0.2 mg/mL DNAse or 5% fetal bovine serum, with liver and kidney ECM as controls, respectively. Acellular matrices were homogenized and dissolved. Each ECM solution was combined with a hyaluronic acid-based hydrogel decorated with heparin (ECM-HA-HP). Cell proliferation and myogenic differentiation capacity of human MPCs were assessed when cells grew on each ECM-HA-HP substrate.
RESULTS: The skeletal muscle ECM-HA-HP substrate significantly enhanced human MPC proliferation, compared to liver-, kidney-or free-ECM-HA-HP substrates. Numbers of myofibers and myotubules significantly increased on muscle ECM-HA-HP substrate compared to other gel substrates. Numbers of MPCs expressing specific muscle cell markers (i.e. myosin, desmin, myoD, and myf5) significantly increased when these cells were cultured on muscle ECM-HA-HP substrate.
CONCLUSIONS: The present study demonstrated that skeletal muscle ECM-HA-HP as a culture substrate is an optimal culture microenvironment similar to the in vivo environment. This makes possible the potential use of skeletal muscle-derived ECM gel to enhance the skeletal muscle repair or cell-based therapy for urethral sphincter tissue regeneration. to repair hypospadias is with one-stage procedure used foreskin in the first year of life or urethral plate substitution using oral mucosa in adulthood. These procedures envisage a high rate of long-term complication. Regenerative medicine and tissue engineering techniques can provide solutions for failed treatments and adverse events by the use of epithelial stem cells cultures. This approach can reduce the invasiveness of tissue withdrawal and urethroplasty supporting wound healing, decreasing post-operative complications. The aim of this study is to demonstrate the safety of oral mucosal stem cell based graft, obtained from a small oral biopsy, for the restoration ofurethral epithelium.
METHODS: Patient's specific keratinocytes were obtained from small autologous oral mucosa biopsies and were expanded on a biological scaffold and chacterized. Preclinical studies on tumorigenicity were completed in vitro tissue models, while in process controls of tissue manufacturing were carried out by immunofluorescence analysis of oral/urethral markers. A phase I/II clinical trial on well-defined selected group of patients was designed to assess the safety and the efficacy of this experimental treatment. The clinical trial was defined in compliance with GMP/GCP European directives.
RESULTS: Preclnical studies excluded any clear chromosomal aberration or transformed cells presence. The defined clinical protocol includes a single administration of culturedtissue through a surgical procedure of penis including wound bed preparation, product application followed by penis reconstruction. The surgical procedures may be followed by a postimplantation treatment (if necessary). At 3 months and one year after the treatment, the defined end points of urethral reconstruction were the improvement in patient's quality of life, evaluate the presence and severity of symptoms, the presence and severity of epithelial inflammation, the improvement of urethral calibre and thecorrection of penile curvature.
CONCLUSIONS: The success of tissue engineering depends on the quality of the cultures used to prepare the grafts. We investigated the quality and the safety of cultured oral and urethral cells by maintenance of their physiological parameters in vitro and a number of controls to be measured during manufacturing, were defined. The phase I/II clinical trial will confirm the appropriateness of design and treatment for failed hypospadia repair, after intergration of epithelial stem cells and by simultaneous autocrine and paracrine stimulation of resident cells.
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